Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin, a big step toward applying for regulatory approval this year. Report
| Published: September 29, 2014 | Sponsored by: Covance
Industry spending on post-authorization studies belies the rapid changes occurring in Phase IV research, driven by an the demand for evidence of safety and effectiveness. Download this Special Report to learn how Phase IV research continues to transform.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!